About: Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
Creator	Momekov, Georgi Momekova, Denitsa
source	MedRxiv
abstract	The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the present report the in vitro antiviral activity end-points are analyzed from the pharmacokinetic perspective. The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1101/2020.04.11.20061804
has license	medrxiv
sha1sum (hex)	e9953c797d2089fa73bb0424a9ae78bf5a7c84cb
schema:url	https://doi.org/10.1101/2020.04.11.20061804
resource representing a document's title	Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
resource representing a document's body	covid:e9953c797d2089fa73bb0424a9ae78bf5a7c84cb#body_text
is schema:about of	named entity 'data' named entity 'PROPOSED' named entity 'excessive' named entity 'pharmacokinetic' named entity 'antiviral' named entity 'COVID-19' named entity 'pharmacokinetic' named entity 'COVID' named entity 'itching' named entity 'SARS-CoV-2' named entity 'pharmacokinetic' named entity 'Antiviral Research' named entity 'endemic areas' named entity 'self-medication' named entity 'COVID-19' named entity 'evidence-based medicine' named entity 'reverberation' named entity 'avermectin' named entity 'pharmacokinetic' named entity 'GABA-mediated' named entity 'ataxia' named entity 'therapeutic strategies' named entity 'neurotransmission' named entity 'µmol' named entity 'Ivermectin' named entity 'natural product' named entity 'ivermectin' named entity 'ivermectin' named entity 'pandemics' named entity 'toxicity' named entity 'COVID-19' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'clinical trials' named entity 'COVID-19' named entity 'pharmacokinetic' named entity 'vomiting' named entity 'fever' named entity 'tachycardia' named entity 'RNA' named entity 'ivermectin' named entity 'self-medication' named entity 'CNS depression' named entity 'influenza virus' named entity 'peer-reviewed' named entity 'blood pressure' named entity 'decision makers' named entity 'chloroquine' named entity 'experimental design' named entity 'peer-reviewed' named entity 'observational studies' named entity 'social media' named entity 'COVID-19' named entity 'Australia' named entity 'SARS-CoV-2' named entity 'hyperkeratotic' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'remdesivir' named entity 'nausea' named entity 'antiviral' named entity 'peer-reviewed' named entity 'paradigm' named entity 'antiviral activity' named entity 'evidence-based medicine' named entity 'molecular weight' named entity 'nanogram' named entity 'preclinical' named entity 'ivermectin' named entity 'pilot experiment' named entity 'medRxiv' named entity 'mydriasis' named entity 'clinical evidence' named entity 'ivermectin' named entity 'COVID-19' named entity 'ivermectin' named entity 'randomized studies' named entity 'antiviral drug' named entity 'parasitic infection' named entity 'tachycardia' named entity 'RNA' named entity 'ivermectin' named entity 'eosinophilia' named entity 'medRxiv'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software